AdultPediatricGeriatricDosage Forms & Strengths tablet (HCL salt) 25mg (generic) 37.5mg (generic) 50mg (generic) 75mg (generic) 100mg (generic) tablet, extended-release (HCL salt) 37.5mg (generic) 75mg (generic) 150mg (generic) 225mg (generic) capsule, extended-release (HCL salt) 37.5mg (Effexor XR, generic) 75mg (Effexor XR, generic) 150mg (Effexor XR, generic) tablet, extended-release (besylate salt) 112.5 mg (Venbysi XR) Major Depressive Disorder Indicated for treatment of major depressive disorder (MDD) Immediate-release tablets 75 mg/day PO divided q8-12hr initially; may be increased by ≤75 mg/day not faster than every 4 days Moderate: Up to 225 mg/day PO divided q8-12hr Severe: Up to 375 mg/day PO divided q8-12hr Extended-release tablets or capsules (HCl salt) 37.5-75 mg PO once daily initially; may be increased by 75 mg/day every 4 days; not to exceed 225 mg/day Extended-release tablets (besylate salt) Do not initiate treatment with venlafaxine besylate extended-release tablets Use another venlafaxine extended-release product for initial dosage, titration, and dosages below 112.5 mg qDay Can be initiated at 112.5 mg PO qDay in patients who have received >75 mg of another venlafaxine extended-release product for at least 4 days Not to exceed 225 mg/day Generalized Anxiety Disorder Indicated for treatment of generalized anxiety disorder (GAD) Extended-release tablets or capsules (HCl salt) 37.5-75 mg PO once daily initially; may be increased by 75 mg/day every 4-7 days; not to exceed 225 mg/day Extended-release tablets (besylate salt) Do not initiate treatment with venlafaxine besylate extended-release tablets Use another venlafaxine extended-release product for initial dosage, titration, and dosages below 112.5 mg qDay Can be initiated at 112.5 mg PO qDay in patients who have received >75 mg of another venlafaxine extended-release product for at least 4 days Not to exceed 225 mg/day Social Anxiety Disorder Indicated for treatment of social anxiety disorder (SAD) Extended-release tablets or capsules (HCl salt): 75 mg PO once daily Dosages >75 mg/day not shown to be more effective Panic Disorder Indicated for treatment of panic disorder, with or without agoraphobia Extended-release tablets or capsules (HCl salt): 37.5 mg PO once daily for 7 days, then 75 mg once daily; may be further increased by 75 mg/day every 7 days; not to exceed 225 mg/day Dosage Modifications Renal impairment Mild or moderate (CrCl 30-89 mL/min): Decrease total daily dose (TDD) by 25-50% Severe (CrCl <30 mL/min or hemodialysis: Decrease TDD by 50% or more Extended-release tablets should not exceed 112.5 mg in patients with renal impairment; if TDD is <112.5 mg/day use another venlafaxine extended-release product Hepatic impairment Mild-to-moderate (Child-Pugh 5-9): Decrease TDD by 50% Severe (Child-Pugh 10-15) or cirrhosis: Owing to individual variability in clearance, it may be necessary to reduce dose by 50% or more Extended-release tablets should not exceed 112.5 mg in patients with hepatic impairment; if TDD is <112.5 mg/day use another venlafaxine extended-release product Hot Flashes Due to Hormonal Chemotherapy (Off-label) Immediate-release: 37.5 mg BID or 75 mg qDay; alternatively may titrate up beginning with 37.5 mg qDay for 1 week then 75 mg daily Extended-release: 37.5-150 mg PO once daily for 4-12 weeks Post-traumatic Stress Disorder (Off-label) Extended-release formulation: 37.5-300 mg/day Attention Deficit Disorder (Off-label) 18.75-75 mg/day; may increase to 150 mg/day after 4 weeks; doses up to 225 mg/day used Neuropathic Pain (Off-label) 75-225 mg/day PO ; onset of relief may start in 1-2 weeks or take up to 6 weeks for full benefitDosage Forms & Strengths tablet (HCl salt) 25mg (generic) 37.5mg (generic) 50mg (generic) 75mg (generic) 100mg (generic) tablet, extended-release (HCl salt) 37.5mg (generic) 75mg (generic) 150mg (generic) 225mg (generic) capsule, extended-release (HCL salt) 37.5mg (Effexor XR, generic) 75mg (Effexor XR, generic) 150mg (Effexor XR, generic) Anxiety (Off-label) Children: 37.5 mg/day PO initially Adolescents: 37.5-75 mg/day PO initially Maintenance: Children, 75-150 mg/day; adolescents, 150-300 mg/day Depression (Off-label) Children: 37.5 mg/day PO initially Adolescents: 37.5-75 mg/day PO initially Maintenance: Children, 75-150 mg/day; adolescents, 150-300 mg/day Attention Deficit Disorder (Off-label) <40 kg: 12.5 mg/day PO initially; increase by 12.5 mg/week; not to exceed 50 mg/day divided twice daily ≥40 kg: 12.5 mg/day PO initially; increase by 25 mg/week; not to exceed 75 mg/day divided three times dailyMajor Depressive Disorder Indicated for treatment of major depressive disorder (MDD) Immediate-release tablets: 25-50 mg/day PO divided q8-12hr initially; may be increased as tolerated by ≤25 mg/day no faster than every 4 days Extended-release tablets or capsules (HCl salt): 37.5 mg PO once daily initially; may be increased by 37.5 mg/day every 4-7 days; not to exceed 225 mg/day Extended-release tablets (besylate salt) Do not initiate treatment with venlafaxine besylate extended-release tablets Use another venlafaxine extended-release product for initial dosage, titration, and dosages below 112.5 mg qDay Can be initiated at 112.5 mg PO qDay in patients who have received >75 mg of another venlafaxine extended-release product for at least 4 days Not to exceed 225 mg/day Generalized Anxiety Disorder Indicated for treatment of generalized anxiety disorder (GAD) Extended-release tablets or capsules (HCl salt): 37.5 mg PO once daily initially; may be increased by 37.5 mg/day every 4 days; not to exceed 225 mg/day Extended-release tablets (besylate salt) Do not initiate treatment with venlafaxine besylate extended-release tablets Use another venlafaxine extended-release product for initial dosage, titration, and dosages below 112.5 mg qDay Can be initiated at 112.5 mg PO qDay in patients who have received >75 mg of another venlafaxine extended-release product for at least 4 days Not to exceed 225 mg/day Social Anxiety Disorder Indicated for treatment of social anxiety disorder (SAD) Extended-release tablets or capsules (HCl salt): 37.5 mg PO once daily; may be increased by 37.5 mg/day every 4 days Panic Disorder Indicated for treatment of panic disorder, with or without agoraphobia Extended-release tablets or capsules (HCl salt): 37.5 mg PO once daily for 7 days, then 75 mg once daily; may be further increased by 37.5 mg/day every 7 days; not to exceed 225 mg/day Dosage Modifications Renal impairment Mild or moderate (CrCl 30-89 mL/min): Decrease total daily dose by 25-50% Severe (CrCl <30 mL/min or hemodialysis: Decrease total daily dose by 50% or more Extended-release tablets should not exceed 112.5 mg in patients with renal impairment; if TDD is <112.5 mg/day use another venlafaxine extended-release product Hepatic impairment Mild-to-moderate (Child-Pugh 5-9): Decrease total daily dose by 50% Severe (Child-Pugh 10-15) or cirrhosis: Owing to individual variability in clearance, it may be necessary to reduce dose by 50% or more Extended-release tablets should not exceed 112.5 mg in patients with hepatic impairment; if TDD is <112.5 mg/day use another venlafaxine extended-release product Interaction CheckerEnter a drug name and venlafaxineNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (8)iobenguane I 123venlafaxine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.isocarboxazidisocarboxazid and venlafaxine both increase serotonin levels. Contraindicated.phenelzinephenelzine and venlafaxine both increase serotonin levels. Contraindicated.posaconazoleposaconazole will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.procarbazineprocarbazine and venlafaxine both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.safinamidevenlafaxine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.selegilineselegiline and venlafaxine both increase serotonin levels. Contraindicated. At least 14 days should elapse between discontinuation of selegiline and initiation of treatment with a serotonergic drug.tranylcyprominetranylcypromine and venlafaxine both increase serotonin levels. Contraindicated.Serious - Use Alternative (106)abametapirabametapir will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir.alfentanilvenlafaxine and alfentanil both increase serotonin levels. Avoid or Use Alternate Drug. May cause serotonin syndromeamiodaroneamiodarone and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.amisulprideamisulpride and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug. ECG monitoring is recommended if coadministered.amitriptylinevenlafaxine and amitriptyline both increase serotonin levels. Avoid or Use Alternate Drug.amoxapinevenlafaxine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.anagrelideanagrelide and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.apalutamideapalutamide will decrease the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.apixabanvenlafaxine and apixaban both increase anticoagulation. Avoid or Use Alternate Drug.arsenic trioxidearsenic trioxide and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.asenapineasenapine and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.asenapine transdermalasenapine transdermal and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphinebuprenorphine and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphine buccalbuprenorphine buccal and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphine subdermal implantbuprenorphine subdermal implant and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphine transdermalbuprenorphine transdermal and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.buprenorphine, long-acting injectionbuprenorphine, long-acting injection and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.bupropionvenlafaxine increases toxicity of bupropion by unspecified interaction mechanism. Avoid or Use Alternate Drug. May lower seizure threshold; keep bupropion dose as low as possible.buspironevenlafaxine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.ceritinibceritinib will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.citalopramcitalopram and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.clarithromycinclarithromycin will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.clomipraminevenlafaxine and clomipramine both increase serotonin levels. Avoid or Use Alternate Drug.cyclobenzaprinevenlafaxine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. desfluranedesflurane and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.desipraminevenlafaxine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.dextromethorphanvenlafaxine will increase the level or effect of dextromethorphan by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.venlafaxine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.disopyramidedisopyramide and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.dolasetrondolasetron, venlafaxine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.dosulepinvenlafaxine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepinvenlafaxine will increase the level or effect of doxepin by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.venlafaxine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.duloxetineduloxetine and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.eliglustateliglustat and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.encorafenibencorafenib and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.entrectinibentrectinib and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.eribulineribulin and venlafaxine both decrease QTc interval. Avoid or Use Alternate Drug.escitalopramescitalopram and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.fentanylvenlafaxine and fentanyl both increase serotonin levels. Avoid or Use Alternate Drug. May cause serotonin syndromefexinidazolefexinidazole will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.fluoxetinefluoxetine and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.fluphenazinefluphenazine and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.fluvoxaminefluvoxamine and venlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.givosirangivosiran will increase the level or effect of venlafaxine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.granisetrongranisetron, venlafaxine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.ibutilideibutilide and venlafaxine both increase QTc interval. Avoid or Use Alternate Drug.idelalisibidelalisib will increase the level or effect of venlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substratesimipraminevenlafaxine and imipramine